Tuesday, 29 October 2019
Amgen posts higher biosimilar sales, ends neuroscience program
By Deena Beasley (Reuters) - Amgen Inc on Tuesday said competition for its older drugs sent third-quarter revenue down 3%, but biosimilar sales were strong and the quarterly results were ahead of Wall Street estimates. The biotechnology company, which last year launched migraine drug Aimovig, also said it would end programs to develop other neuroscience drugs
The post Amgen posts higher biosimilar sales, ends neuroscience program appeared first on Firstpost.
from Firstpost https://ift.tt/36iVX9c
Subscribe to:
Post Comments
(
Atom
)
No comments :
Post a Comment